Figure 3 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

Résumé fourni par la source

CD4+ T cells drive sensitization of qM tumors lacking CD73 to anti-CTLA4 ICB. A, Schema and tumor kinetics for sgCD73 tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. B, Schema and tumor kinetics for sgCD73 tumors propagated in WT or CD4-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. C, Schema and tumor kinetics for sgCD73 tumors propagated in WT or MHC-II-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. D, Schema and tumor kinetics for SnailHI qM tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. E, Schema and tumor kinetics for SnailHI qM tumors propagated in WT or CD4-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. F–I, Flow cytometry analysis for (F and H) IFNγ and (G and I) T-BET expression on CD4+ T cells as determined by flow cytometry from SnailHI qM control or sgCD73 tumor-bearing mice treated with the indicated antibodies. Tumors were harvested at 2 weeks (F and G) or 4 weeks (H and I) after treatment. Data represent three independent experiments in which n = 3–8 for each group. A–E, Data represent the SEM, two-way ANOVA, **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. F–I, Data represent the SEM, two-way ANOVA, with Tukey's multiple comparisons test *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.